A Clinical Trial to Evaluate the Effects of the Synbiotic Dual Cap® on Gastrointestinal Comfort in Adults Initiating GLP-1 or Dual-Incretin Therapy for Weight Loss.
Epetome
Summary
This is a decentralized, single-group, open-label clinical trial evaluating the effects of the Synbiotic Dual Cap® in 40 adults who have initiated GLP-1 or dual-incretin therapy within the preceding 60 days and who are experiencing at least one associated gastrointestinal symptom. All participants will receive the Synbiotic Dual Cap® (1 capsule daily, taken in the morning without food) alongside their existing GLP-1 medication for 12 consecutive weeks. Participants will complete study-specific questionnaires at four assessment timepoints: Baseline, Week 4, Week 8, and Week 12. No placebo control arm is included; all efficacy comparisons are within-subject against Baseline values. The study is conducted entirely remotely via the Citruslabs digital platform, with the study product shipped directly to participants' homes.
Eligibility
- Age range
- 18–65 years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Adults aged 18-65 years. * Have initiated a GLP-1 receptor agonist or dual-incretin medication for weight loss (including but not limited to semaglutide, tirzepatide, or liraglutide) within the last 60 days prior to the date of enrollment. * Self-reported experience of at least one gastrointestinal symptom associated with GLP-1 initiation, including nausea, bloating, constipation, diarrhea, or general digestive discomfort, at the time of screening. * Currently on a stable GLP-1 dose as directed by their prescribing physician. * Willing to take one Synbiotic Dual Cap® dai…
Interventions
- Dietary SupplementSynbiotic Dual Cap® Intervention
Participants will take 1 capsule each morning, without food and without a hot drink, for 12 consecutive weeks alongside their existing GLP-1 medication.
Location
- CitruslabsLas Vegas, Nevada